Drugs / COM701
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04354246 | Mar 2020 → Apr 2026 | colon carcinoma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer +1 | Compugen Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03667716 | Sep 2018 → Jan 2024 | colorectal cancer, endometrial cancer, lung cancer, ovarian cancer +1 | Compugen Ltd | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06888921 | Jul 2025 → Mar 2027 expected | ovarian carcinoma | Compugen Ltd | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04570839 | Aug 2020 → May 2024 | endometrium neoplasm, head and neck cancer, ovarian cancer | Compugen Ltd | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COM701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04570839 ↗ |
| Known as | CGEN-15029 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594534 ↗ |
| Known as | Pvrig inhibitor com701 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594534 ↗ |
| Action | Inhibit | “an inhibitor of poliovirus receptor related immunoglobulin domain containing (PVRIG)” NCT03667716 ↗ |
| Modality | Monoclonal antibody | “experimental COM701 antibody” NCT06888921 ↗ |
| Route | Intravenous | “COM701 monotherapy sequential dose escalation administered IV every 3 weeks” NCT03667716 ↗ |
| Target | PVRIG | “an inhibitor of poliovirus receptor related immunoglobulin domain containing (PVRIG)” NCT03667716 ↗ |